Research location
Subiaco
Western Australia, Australia
Advertisement
Research activity in Subiaco
Western Australia, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 64 trials and 64 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Subiaco
64 linked trials · page 1 of 2Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerNCT06892548 · 2025-05-02 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287 · 2025-02-04 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064 · 2024-04-10 · 1 site observation
RECRUITING
A Prospective, Pre-market, Multi-center Study of Insignia Hip Stem in THA to Determine Implant Survivorship and PROMS.NCT06108934 · 2024-02-22 · 1 site observation
RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029 · 2023-10-13 · 1 site observation
RECRUITING
Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · 2020-11-16 · 1 site observation
RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerNCT05635708 · 2023-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationNCT05480865 · 2022-07-06 · 1 site observation
TERMINATED
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · 2022-02-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerNCT04619004 · 2021-02-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).NCT04303780 · 2020-06-04 · 1 site observation
COMPLETED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04177108 · 2019-11-25 · 1 site observation
COMPLETED
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)NCT03635567 · 2018-10-25 · 1 site observation
COMPLETED
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]NCT03529110 · 2018-08-09 · 1 site observation
COMPLETED
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]NCT03523585 · 2018-08-01 · 1 site observation
COMPLETED
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])NCT03517449 · 2018-06-11 · 1 site observation
COMPLETED
Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF AgentsNCT03470688 · 2018-03-01 · 1 site observation
UNKNOWN
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934 · 2017-06-13 · 1 site observation
COMPLETED
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsNCT03102320 · 2017-05-26 · 1 site observation
COMPLETED
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCNCT03057106 · 2017-03-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineNCT02915744 · 2016-11-01 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based TherapyNCT02924883 · 2016-09-26 · 1 site observation
COMPLETED
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeNCT02847728 · 2016-07-28 · 1 site observation
COMPLETED
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCNCT02504489 · 2015-12-01 · 1 site observation
COMPLETED
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsNCT02576431 · 2015-09-30 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)NCT02425891 · 2015-06-23 · 1 site observation
COMPLETED
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · 2015-02-24 · 1 site observation
COMPLETED
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung CancerNCT02259582 · 2015-02-01 · 1 site observation
COMPLETED
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)NCT02245568 · 2014-08-01 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerNCT02107703 · 2014-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277 · 2014-04-02 · 1 site observation
COMPLETED
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)NCT02043665 · 2013-12-18 · 1 site observation
COMPLETED
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus PlaceboNCT01900665 · 2013-07-01 · 1 site observation
TERMINATED
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyNCT01677754 · 2012-10-24 · 1 site observation
COMPLETED
Study of AeroForm Tissue Expander for Breast ReconstructionNCT01903174 · 2012-06-01 · 1 site observation
COMPLETED
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443 · 2012-03-01 · 1 site observation
TERMINATED
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to MethotrexateNCT01500278 · 2011-12-01 · 1 site observation
COMPLETED
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.NCT01475721 · 2011-11-18 · 1 site observation
COMPLETED
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldNCT01462344 · 2011-11-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.